Strategies for the prevention of recurrent hepatitis B virus infection after liver transplantation

Gastroenterology and Hepatology

Volumn 10, Issue 3, 2014, Pages 175-179

  Manne, Vignan ^a   Allen, Ruby M ^a   Saab, Sammy ^a  

^a UNIVERSITY OF CALIFORNIA   (United States)

Author keywords

Hepatitis B virus; Hepatocellular carcinoma; Liver transplantation; Posttransplantation; Prevention; Risk factors

Indexed keywords

ADEFOVIR; ANTIVIRUS AGENT; ENTECAVIR; HEPATITIS B ANTIBODY; HEPATITIS B SURFACE ANTIGEN; HEPATITIS B(E) ANTIGEN; LAMIVUDINE; NUCLEOSIDE ANALOG; NUCLEOTIDE DERIVATIVE; PREDNISONE; TELBIVUDINE; TENOFOVIR; VIRUS DNA;

ANTIVIRAL RESISTANCE; ANTIVIRAL THERAPY; ARTICLE; CORTICOSTEROID THERAPY; DECOMPENSATED LIVER CIRRHOSIS; DISEASE ASSOCIATION; DISEASE COURSE; DNA DETERMINATION; DRUG EFFICACY; HEPATITIS B; HIGH RISK PATIENT; HUMAN; IMMUNOPROPHYLAXIS; IMMUNOSUPPRESSIVE TREATMENT; INFECTION PREVENTION; LIVER CIRRHOSIS; LIVER GRAFT; LIVER TRANSPLANTATION; MONOTHERAPY; POLYMERASE CHAIN REACTION; POSTOPERATIVE INFECTION; RECURRENCE RISK; RECURRENT INFECTION; VIRUS DIAGNOSIS; VIRUS LOAD;

EID: 84898662055     PISSN: 15547914     EISSN: None     Source Type: Journal    
DOI: None     Document Type: Article

References (52)

1. Hepatitis B. World Health Organization. http://www.who.int/mediacentre/ factsheets/fs204/en/. Updated July 2013. Accessed August 5, 2013.
2. Viral hepatitis statistics and surveillance. Centers for Disease Control and Prevention. http://www.cdc.gov/hepatitis/Statistics/index.htm. Updated August 2013. Accessed August 5, 2013.
3. Bosch FX, Ribes J, Cléries R, Díaz M. Epidemiology of hepatocellular carcinoma. Clin Liver Dis. 2005;9(2):191-211, v.
4. Brooks J, Gelson W, Rushbrook SM. Therapeutic advances in the management of chronic hepatitis B infection. Ther Adv Chronic Dis. 2013;4(4):157-166.
5. Pfitzmann R, Nüssler NC, Hippler-Benscheidt M, Neuhaus R, Neuhaus P. Long-term results after liver transplantation. Transpl Int. 2008;21(3):234-246. (Pubitemid 351197348)
6. O'Grady JG, Smith HM, Davies SE, et al. Hepatitis B virus reinfection after orthotopic liver transplantation. Serological and clinical implications. J Hepatol. 1992;14(1):104-111.
7. Todo S, Demetris AJ, Van Thiel D, Teperman L, Fung JJ, Starzl TE. Orthotopic liver transplantation for patients with hepatitis B virus-related liver disease. Hepatology. 1991;13(4):619-626.
8. Lucey MR, Graham DM, Martin P, et al. Recurrence of hepatitis B and delta hepatitis after orthotopic liver transplantation. Gut. 1992;33(10):1390-1396.
9. Beckebaum S, Sotiropoulos GC, Gerken G, Cicinnati VR. Hepatitis B and liver transplantation: 2008 update. Rev Med Virol. 2009;19(1):7-29.
10. Yilmaz N, Shiffman ML, Stravitz TR, et al. Prophylaxsis against recurrance of hepatitis B virus after liver transplantation: a retrospective analysis spanning 20 years. Liver Int. 2008;28(1):72-78.
11. Coffin CS, Terrault NA. Management of hepatitis B in liver transplant recipients. J Viral Hepat. 2007;14(suppl 1):37-44. (Pubitemid 47624113)
12. Cholongitas E, Goulis J, Akriviadis E, Papatheodoridis GV. Hepatitis B immunoglobulin and/or nucleos(t)ide analogues for prophylaxis against hepatitis B virus recurrence after liver transplantation: a systematic review. Liver Transpl. 2011;17(10):1176-1190.
13. McMillan JS, Shaw T, Angus PW, Locarnini SA. Effect of immunosuppressive and antiviral agents on hepatitis B virus replication in vitro. Hepatology. 1995;22(1):36-43.
14. Tur-Kaspa R, Burk RD, Shaul Y, Shafritz DA. Hepatitis B virus DNA contains a glucocorticoid-responsive element. Proc Natl Acad Sci U S A. 1986;83(6):1627-1631. (Pubitemid 16018617)
15. Tur-Kaspa R, Shaul Y, Moore DD, et al. The glucocorticoid receptor recognizes a specific nucleotide sequence in hepatitis B virus DNA causing increased activity of the HBV enhancer. Virology. 1988;167(2):630-633. (Pubitemid 19037154)
16. Omata M. Significance of extrahepatic replication of hepatitis B virus. Hepatology. 1990;12(2):364-366. (Pubitemid 20285802)
17. Wu LM, Xu X, Zheng SS. Hepatitis B virus reinfection after liver transplantation: related risk factors and perspective. Hepatobiliary Pancreat Dis Int. 2005;4(4):502-508. (Pubitemid 41723801)
18. Samuel D, Muller R, Alexander G, et al. Liver transplantation in European patients with the hepatitis B surface antigen. N Engl J Med. 1993;329(25):1842-1847. (Pubitemid 23360483)
19. Steinmüller T, Seehofer D, Rayes N, et al. Increasing applicability of liver transplantation for patients with hepatitis B-related liver disease. Hepatology. 2002;35(6):1528-1535. (Pubitemid 34966909)
20. Degertekin B, Han SH, Keeffe EB, et al NIH HBV-OLT Study Group. Impact of virologic breakthrough and HBIG regimen on hepatitis B recurrence after liver transplantation. Am J Transplant. 2010;10(8):1823-1833.
21. McGory RW, Ishitani MB, Oliveira WM, et al. Improved outcome of orthotopic liver transplantation for chronic hepatitis B cirrhosis with aggressive passive immunization. Transplantation. 1996;61(9):1358-1364. (Pubitemid 26152826)
22. Marzano A, Gaia S, Ghisetti V, et al. Viral load at the time of liver transplantation and risk of hepatitis B virus recurrence. Liver Transpl. 2005;11(4):402-409. (Pubitemid 40533208)
23. Fung J, Cheung C, Chan SC, et al. Entecavir monotherapy is effective in suppressing hepatitis B virus after liver transplantation. Gastroenterology. 2011;141(4):1212-1219.
24. Faria LC, Gigou M, Roque-Afonso AM, et al. Hepatocellular carcinoma is associated with an increased risk of hepatitis B virus recurrence after liver transplantation. Gastroenterology. 2008;134(7):1890-1899, quiz 2155.
25. Saab S, Yeganeh M, Nguyen K, et al. Recurrence of hepatocellular carcinoma and hepatitis B reinfection in hepatitis B surface antigen-positive patients after liver transplantation. Liver Transpl. 2009;15(11):1525-1534.
26. Demetris AJ, Todo S, Van Thiel DH, et al. Evolution of hepatitis B virus liver disease after hepatic replacement. Practical and theoretical considerations. Am J Pathol. 1990;137(3):667-676. (Pubitemid 20280996)
27. Yi NJ, Lee KW, Kong SY, et al. Outcome of various treatments for posttransplant hepatitis B virus recurrence. World J Surg. 2013;37(4):812-819.
28. Wong SN, Chu CJ, Wai CT, et al. Low risk of hepatitis B virus recurrence after withdrawal of long-term hepatitis B immunoglobulin in patients receiving maintenance nucleos(t)ide analogue therapy. Liver Transpl. 2007;13(3):374-381. (Pubitemid 46444466)
29. Marzano A, Salizzoni M, Debernardi-Venon W, et al. Prevention of hepatitis B virus recurrence after liver transplantation in cirrhotic patients treated with lamivudine and passive immunoprophylaxis. J Hepatol. 2001;34(6):903-910. (Pubitemid 32595191)
30. Roche B, Feray C, Gigou M, et al. HBV DNA persistence 10 years after liver transplantation despite successful anti-HBS passive immunoprophylaxis. Hepatology. 2003;38(1):86-95. (Pubitemid 36775799)
31. Starzl TE, Demetris AJ, Van Thiel D. Liver transplantation. N Engl J Med. 1989;321(15):1014-1022.
32. Liaw YF, Sheen IS, Lee CM, et al. Tenofovir disoproxil fumarate (TDF), emtricitabine/TDF, and entecavir in patients with decompensated chronic hepatitis B liver disease. Hepatology. 2011;53(1):62-72.
33. Terrault NA, Zhou S, Combs C, et al. Prophylaxis in liver transplant recipients using a fixed dosing schedule of hepatitis B immunoglobulin. Hepatology. 1996;24(6):1327-1333. (Pubitemid 26399024)
34. Gane EJ, Angus PW, Strasser S, et al Australasian Liver Transplant Study Group. Lamivudine plus low-dose hepatitis B immunoglobulin to prevent recurrent hepatitis B following liver transplantation. Gastroenterology. 2007;132(3):931-937. (Pubitemid 46440868)
35. Anderson RD, Chinnakotla S, Guo L, Perrillo RP, Klintmalm GB, Davis GL. Intramuscular hepatitis B immunoglobulin (HBIG) and nucleosides for prevention of recurrent hepatitis B following liver transplantation: comparison with other HBIG regimens. Clin Transplant. 2007;21(4):510-517. (Pubitemid 47161828)
36. Angus PW, McCaughan GW, Gane EJ, Crawford DH, Harley H. Combination low-dose hepatitis B immune globulin and lamivudine therapy provides effective prophylaxis against posttransplantation hepatitis B. Liver Transpl. 2000;6(4):429-433. (Pubitemid 30489114)
37. Nath DS, Kalis A, Nelson S, Payne WD, Lake JR, Humar A. Hepatitis B prophylaxis post-liver transplant without maintenance hepatitis B immunoglobulin therapy. Clin Transplant. 2006;20(2):206-210.
38. Angus PW, Patterson SJ, Strasser SI, McCaughan GW, Gane E. A randomized study of adefovir dipivoxil in place of HBIG in combination with lamivudine as postliver transplantation hepatitis B prophylaxis. Hepatology. 2008;48(5):1460-1466.
39. Teperman LW, Poordad F, Bzowej N, et al. Randomized trial of emtricitabine/tenofovir disoproxil fumarate after hepatitis B immunoglobulin withdrawal after liver transplantation. Liver Transpl. 2013;19(6):594-601.
40. Saab S, Desai S, Tsaoi D, et al. Posttransplantation hepatitis B prophylaxis with combination oral nucleoside and nucleotide analog therapy. Am J Transplant. 2011;11(3):511-517.
41. Choe WH, Kwon SY, Kim BK, et al. Tenofovir plus lamivudine as rescue therapy for adefovir-resistant chronic hepatitis B in hepatitis B e antigen-positive patients with liver cirrhosis. Liver Int. 2008;28(6):814-820. (Pubitemid 351818643)
42. Neff GW, Kemmer N, Kaiser TE, et al. Combination therapy in liver transplant recipients with hepatitis B virus without hepatitis B immune globulin. Dig Dis Sci. 2007;52(10):2497-2500. (Pubitemid 47373893)
43. Shiffman ML, Stravitz RT, Kimmel M, et al. Tenofovir plus emtricitabine (truvada) prevents recurrence of hepatitis B virus (HBV) in liver transplant (LT) recipients after discontinuing hepatitis B immune globulin (HBIg) [abstract]. Hepatology. 2009;50:392A.
44. Karlas T, Hartmann J, Weimann A, et al. Prevention of lamivudine-resistant hepatitis B recurrence after liver transplantation with entecavir plus tenofovir combination therapy and perioperative hepatitis B immunoglobulin only. Transpl Infect Dis. 2011;13(3):299-302.
45. Wadhawan M, Gupta S, Goyal N, Taneja S, Kumar A. Living related liver transplantation for hepatitis B-related liver disease without hepatitis B immune globulin prophylaxis. Liver Transpl. 2013;19(9):1030-1035.
46. Schiff E, Lai CL, Hadziyannis S, et al Adefovir Dipivoxil Study 45 International Investigators Group. Adefovir dipivoxil for wait-listed and post-liver transplantation patients with lamivudine-resistant hepatitis B: final long-term results. Liver Transpl. 2007;13(3):349-360. (Pubitemid 46444463)
47. Angus P, Vaughan R, Xiong S, et al. Resistance to adefovir dipivoxil therapy associated with the selection of a novel mutation in the HBV polymerase. Gastroenterology. 2003;125(2):292-297. (Pubitemid 36929407)
48. Villeneuve JP, Durantel D, Durantel S, et al. Selection of a hepatitis B virus strain resistant to adefovir in a liver transplantation patient. J Hepatol. 2003;39(6):1085-1089. (Pubitemid 37523785)
49. Lacombe K, Ollivet A, Gozlan J, et al. A novel hepatitis B virus mutation with resistance to adefovir but not to tenofovir in an HIV-hepatitis B virus-co-infected patient. AIDS. 2006;20(17):2229-2231. (Pubitemid 44684715)
50. Borroto-Esoda K, Miller MD, Arterburn S. Pooled analysis of amino acid changes in the HBV polymerase in patients from four major adefovir dipivoxil clinical trials. J Hepatol. 2007;47(4):492-498. (Pubitemid 47334760)
51. Fung SK, Chae HB, Fontana RJ, et al. Virologic response and resistance to adefovir in patients with chronic hepatitis B. J Hepatol. 2006;44(2):283-290. (Pubitemid 43069209)
52. Vargas HE, Dodson FS, Rakela J. A concise update on the status of liver transplantation for hepatitis B virus: the challenges in 2002. Liver Transpl. 2002;8(1):2-9. (Pubitemid 34092666)